SecBot SecBot
6-K ·Filed Jul 9, 2026

MESO

MESOBLAST LTD
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001345099-26-000064
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong revenue ramp from the first FDA-approved MSC therapy is a clear de-risking event for Mesoblast's commercial model. With Q4 alone generating US$36M, the annualized run-rate already exceeds US$144M. Monitor the final audited figures and any guidance for FY2027 as label expansion catalysts (adult SR-aGvHD, IBD) remain on the horizon. The strong preliminary results reduce cash-burn concerns and support pipeline funding.

DirectionBullish
Confidencemedium
Horizonweeks

Ryoncil

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already on the market — FDA-approved December 18, 2024, commercially launched in the US from March 2025.
Next catalyst
None dated

What to watchRyoncil is already delivering real revenue ($110-120M annualized) but the stock also carries very high short interest (~83% short ratio). Watch quarterly revenue growth trajectory and gross margins as the proxy for commercial success; the next true binary catalysts are 12+ months away from other pipeline drugs. Recent insider buying from director George Gregory and institutional accumulation (Bank of America, UBS, BlackRock) provide some confidence in the commercial trajectory.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.44
T+0 close · Jul 9, 2026 · via day close
Latest settled
−7.90%
T+60 · $14.22
Vs SPY
−10.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $15.44entry
  2. T+1 · 4mo ago +5.05%α +5.82% · $16.22
  3. T+5 · 4mo ago +15.67%α +16.23% · $17.86
  4. T+20 · 3mo ago +3.24%α +0.81% · $15.94
  5. T+60 · 6w ago −7.90%α −10.53% · $14.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast reported Ryoncil net revenue of US$36M for Q4 and US$115M for FY2026 ending June 30, 2026. The filing is a preliminary estimate subject to audit, and management guided for continued revenue growth. The company also noted a strong capital position and a new five-year facility.

Key Facts

  • Ryoncil net revenue of US$36 million for Q4 FY2026 (quarter ended June 30, 2026)
  • Full-year FY2026 Ryoncil net revenue of US$115 million
  • Results are preliminary estimates, subject to completion of year-end closing and audit procedures
  • Management anticipates continued revenue growth in the coming fiscal year
  • Company stated capital position is strong and operational activities are well funded through revenue growth

Financial Impact

Q4 Ryoncil net revenue of US$36M; full-year FY2026 net revenue of US$115M

revenue

Risk Factors

  • Results are preliminary and subject to audit adjustments
  • Single-product revenue concentration (Ryoncil) creates dependency risk
  • Forward-looking statements about revenue growth are not guaranteed

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001345099-26-000064
Exhibit: exhibit991ryoncilsalesup.htm0001345099-26-000064
Document: 0001345099-26-000064-index-headers.html0001345099-26-000064
Document: 0001345099-26-000064-index.html0001345099-26-000064
Document: 0001345099-26-000064.txt0001345099-26-000064

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 10, 2026